Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Short term Debt (2016 - 2018)

Niagen Bioscience (NAGE) has disclosed Short term Debt for 3 consecutive years, with $137000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Short term Debt fell 55.81% to $137000.0 in Q4 2018 year-over-year; TTM through Dec 2018 was $137000.0, a 55.81% decrease, with the full-year FY2018 number at $137000.0, down 55.81% from a year prior.
  • Short term Debt was $137000.0 for Q4 2018 at Niagen Bioscience, down from $310000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.5 million in Q1 2016 to a low of $137000.0 in Q4 2018.
  • A 3-year average of $658526.0 and a median of $310000.0 in 2017 define the central range for Short term Debt.
  • Biggest YoY gain for Short term Debt was 55.81% in 2018; the steepest drop was 55.81% in 2018.
  • Niagen Bioscience's Short term Debt stood at $1.5 million in 2016, then tumbled by 79.72% to $310000.0 in 2017, then plummeted by 55.81% to $137000.0 in 2018.
  • Per Business Quant, the three most recent readings for NAGE's Short term Debt are $137000.0 (Q4 2018), $310000.0 (Q4 2017), and $1.5 million (Q1 2016).